Jazz Pharmaceuticals buys Chimerix for $935 million
The company’s cannabis drug, epidiolex, represents 25% of its sales.
The post Jazz Pharmaceuticals buys Chimerix for $935 million appeared first on Green Market Report.
The company’s cannabis drug, epidiolex, represents 25% of its sales.
The post Jazz Pharmaceuticals buys Chimerix for $935 million appeared first on Green Market Report.
